A Study of the Effect of Estrogen-Based Contraceptive Therapy on Total and Free Serum Cortisol Levels in Healthy Women

Overview

About this study

The purpose of this study is to determine the effect of estrogen-based contraceptive therapy on baseline and peak total and free cortisol levels in healthy women undergoing the Cosyntropin stimulation test.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria 

  • Normal menstrual cycle prior to OCP initiation
  • Perceived and documented state of good health
  • Ability and desire to undergo Cosyntropin stimulation testing at baseline and at least 6 weeks after initiation or discontinuation of OCP therapy

Exclusion Criteria         

  • Contraindication or sensitivity to Cosyntropin
  • Poorly controlled diabetes mellitus defined as HbA1c >7.5%,
  • Use of exogenous glucocorticoid medication or Megace within the last 12 months
  • Adrenal insufficiency
  • Current glucocorticoid use
  • Liver disease
  • Chronic renal insufficiency
  • Hyperthyroidism
  • Anorexia nervosa
  • Current inflammatory state
  • Active malignancy
  • Pregnancy
  • BMI <18 or >40 kg/m2

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Irina Bancos, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20304382

Mayo Clinic Footer